Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
VYOME HOLDINGS INC (HIND)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.63-6.32%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HIND yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful integration of acquisitions and note purchase | A primary condition in VYOME HOLDINGS INC's published investment case. The stated target is Complete integration and progress on Humanyze acquisition by 2026. | Improving | Acquisition integration fails or is delayed beyond 2026 | Qualitative: Definitive agreement signed Feb 2026; Q1/Q2 2026 earnings beats reported Definitive agreement signed Feb 2026; Q1/Q2 2026 earnings beats; no integration delays reported. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making development-stage healthcare business, with potential value tied to pipeline progress rather than current profits. The thesis is intact, supported by recent strong performance, but volatile management signals and a recent CEO transition add uncertainty.
The valuation model shows HIND at a 10.6% premium to peers, with low confidence and an expectations gap leaning negative. The market appears to recognize pipeline optionality, but the evidence does not show that current results support a clear valuation discount.
Near term, recent earnings beats and an improved sector backdrop are supportive, while revenue fell between the first and second quarters of 2026 even as the net loss narrowed. Management remains focused on advancing VT-1953 and has increased cash while maintaining no debt, but the next report carries elevated miss risk and a guidance cut would be a meaningful setback.
Over the multi-year view, a key swing factor is whether VT-1953 advances toward pivotal-stage readiness; the two newly licensed JAK inhibitor assets may add pipeline options, but their financial impact is not yet reported. Near term, the thesis is also exposed to weaker jobs data and possible recession fears, while continued strength from healthcare bellwethers could support the sector backdrop.
The 1-3 year view is intact but fragile: recent results and sector conditions help, while losses, falling revenue, management volatility, and clinical execution keep risk high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Litigation issues are resolved or do not worsen | It is working to resolve litigation issues. | Under Pressure | New major litigation filings or worsening legal issues | 1 new litigation filing vs 0 target Litigation filed event on 2026-02-13; no subsequent resolution news. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $2.2 billion by FY26 | A primary condition in VYOME HOLDINGS INC's published investment case. The stated target is >=2200 USD_MILLIONS. | Intact | Revenue falls below $2.2 billion in FY26 | Revenue: $26,955 FY2026-Q2; GAAP. Published target: >=2200 USD_MILLIONS. Target period ends 2026-12-31; this observation covers 2026-Q2. Aug 12, 202626,955 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.92 → $-0.84 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.92 | $500,000 | 1 / 1 |
| 2026-07-25 | $-0.92 | $500,000 | 1 / 1 |
| 2026-07-26 | $-0.92 | $500,000 | 1 / 1 |
| 2026-07-27 | $-0.92 | $500,000 | 1 / 1 |
| 2026-07-28 | $-0.92 | $500,000 | 1 / 1 |
| 2026-07-29 | $-0.92 | $500,000 | 1 / 1 |
| 2026-07-30 | $-0.92 | $250,000 | 2 / 2 |
| 2026-07-31 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-01 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-02 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-03 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-04 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-05 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-06 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-07 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-08 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-09 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-10 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-12 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-13 | $-0.92 | $250,000 | 2 / 2 |
| 2026-08-14 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-15 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-16 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-17 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-18 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-19 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-20 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-21 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-22 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-23 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-24 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-25 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-26 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-27 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-28 | $-0.92 | $500,000 | 1 / 1 |
| 2026-08-29 | $-0.77 | $500,000 | 1 / 1 |
| 2026-08-30 | $-0.77 | $500,000 | 1 / 1 |
| 2026-08-31 | $-0.77 | $500,000 | 1 / 1 |
| 2026-09-01 | $-0.77 | $500,000 | 1 / 1 |
| 2026-09-02 | $-0.77 | $500,000 | 1 / 1 |
| 2026-09-03 | $-0.77 | $500,000 | 1 / 1 |
| 2026-09-04 | $-0.77 | $500,000 | 1 / 1 |
| 2026-09-05 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-06 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-07 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-08 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-09 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-10 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-11 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-12 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-13 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-14 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-15 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-16 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-17 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-18 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-19 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-20 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-21 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-22 | $-0.71 | $250,000 | 2 / 2 |
| 2026-09-23 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-24 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-25 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-26 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-27 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-28 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-29 | $-0.74 | $250,000 | 2 / 2 |
| 2026-09-30 | $-0.74 | $250,000 | 2 / 2 |
| 2026-10-01 | $-0.74 | $250,000 | 2 / 2 |
| 2026-10-02 | $-0.74 | $250,000 | 2 / 2 |
| 2026-10-03 | $-0.74 | $250,000 | 2 / 2 |
| 2026-10-04 | $-0.74 | $250,000 | 2 / 2 |
| 2026-10-05 | $-0.74 | $250,000 | 2 / 2 |
| 2026-10-06 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-07 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-08 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-09 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-10 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-11 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-12 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-13 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-14 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-15 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-16 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-17 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-18 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-19 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-20 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-21 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-22 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-23 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-24 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-25 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-26 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-27 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-28 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-29 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-30 | $-0.84 | $250,000 | 2 / 2 |
| 2026-10-31 | $-0.84 | $250,000 | 2 / 2 |
| 2026-11-01 | $-0.84 | $250,000 | 2 / 2 |
| 2026-11-02 | $-0.84 | $250,000 | 2 / 2 |
| 2026-11-03 | $-0.84 | $250,000 | 2 / 2 |
| 2026-11-04 | $-0.84 | $250,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.